Scalable 3D bioprinting of human islets in a pancreatic decellularized extracellular matrix-enriched bioink for beta-cell replacement therapy
Acta Biomaterialia · 2026-09 · 222 · 327-339
DOI: 10.1016/j.actbio.2026.08.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-09. Verfasst von Wonwoo Jeong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA. Hauptthemen laut MEDLINE: Printing, Three-Dimensional, Bioprinting, Islets of Langerhans, Decellularized Extracellular Matrix. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Juvenile Diabetes Research Foundation Canada, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Allogeneic cell transplantation such as beta-cell replacement for treatment of type 1 diabetes (T1D) is constrained by poor graft survival and functionality, immune rejection, and the lack of scalable biomanufacturing processes. Here, we engineered functional human islet constructs that replicate the physiomimetic human pancreatic microenvironment by employing a clinically-scalable 3D bioprinting system. To support human islet viability and function, we developed alginate-based bioinks incorporating human pancreatic decellularized extracellular matrix (dECM). These bioink formulations were optimized for shear-thinning properties for extrusion of human islets (HI), as well as selective permeability that supports nutrient and therapeutic molecule exchange. Extrusion-based printing parameters were refined to minimize shear stress-induced damage to human islets. The resulting bioprinted pancreatic constructs demonstrated robust structural integrity, high human islet viability (>85%), and long-term glucose-stimulated insulin secretion (GSIS) over a 21-days in vitro culture period, even at a high islet packing density (10,000 islet equivalent/mL) while free islet controls displayed a significant functional decline. The higher performance of bioprinted islets maybe attributable to the supportive 3D dECM-rich microenvironment mitigating culture-induced stress by recapitulating the islet pancreatic niche. This scalable 3D dECM-alginate bioprinted platform represents a new advanced functional material for advancing clinically translatable bio-artificial pancreas therapies for T1D. STATEMENT OF SIGNIFICANCE: Type 1 diabetes affects millions of people worldwide, yet cell-based therapies remain limited by poor graft survival and the lack of scalable manufacturing methods. This study introduces a clinically scalable 3D bioprinting strategy that embeds human pancreatic islets within a biomimetic, decellularized pancreas enriched bioink. Unlike previous approaches, this platform preserves islet viability and glucose-responsive insulin secretion over long-term culture, even at high, clinically relevant islet densities. By combining optimized bioprinting parameters with a pancreas-specific extracellular matrix, this work overcomes key trade-offs between printability, mass transport, and islet function. These findings represent an important step toward manufacturable, bioengineered pancreatic constructs for next-generation diabetes cell replacement therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA.
- Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA; Departement of Surgery, Section of Transplantation, Wake Forest School of Medicine, Winston Salem, NC,…
- Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
- Wake Forest University, Winston Salem, NC, USA.
- Imagine Islet Center, Imagine Pharma, Pittsburgh, PA, United States.
- Department of Pathology, Atrium Health Wake Forest School of Medicine, Winston-Salem, NC, USA.
Förderung
- NIDDK NIH HHS
- Juvenile Diabetes Research Foundation Canada
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Jeong, W., Perrier, Q., Rengaraj, A., Byers, L., Gonzalez, G. C., Peveri, E., Miller, J., Bottino, R., Mikhailov, A. V., Fraker, C., Opara, E. C., Tomei, A. A., Lee, S. J., Orlando, G., & Asthana, A. (2026). Scalable 3D bioprinting of human islets in a pancreatic decellularized extracellular matrix-enriched bioink for beta-cell replacement therapy. Acta Biomaterialia, 222, 327-339. https://doi.org/10.1016/j.actbio.2026.08.008
Vancouver
Jeong W, Perrier Q, Rengaraj A, Byers L, Gonzalez GC, Peveri E, et al. Scalable 3D bioprinting of human islets in a pancreatic decellularized extracellular matrix-enriched bioink for beta-cell replacement therapy. Acta Biomaterialia. 2026;222:327-339. doi:10.1016/j.actbio.2026.08.008
BibTeX
@article{Jeong2026,
author = {Jeong, Wonwoo and Perrier, Quentin and Rengaraj, Arunkumar and Byers, Lori and Gonzalez, Grisell C and Peveri, Emma and Miller, Jake and Bottino, Rita and Mikhailov, Alexei V and Fraker, Christopher and Opara, Emmanuel C and Tomei, Alice A and Lee, Sang Jin and Orlando, Giuseppe and Asthana, Amish},
title = {Scalable 3D bioprinting of human islets in a pancreatic decellularized extracellular matrix-enriched bioink for beta-cell replacement therapy},
journal = {Acta Biomaterialia},
year = {2026},
volume = {222},
pages = {327--339},
doi = {10.1016/j.actbio.2026.08.008}
}
EUVIMED